Drug trial halted after testing for rare kidney conditions
NCT ID NCT02682407
Summary
This study tested an experimental drug called OMS721 (narsoplimab) in adults with four serious kidney diseases. The main goals were to check the drug's safety and see if it could reduce harmful protein in the urine, a key sign of kidney damage. The trial was terminated early and involved 31 participants who received the drug by injection.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LN are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Omeros Investigational Site
Denver, Colorado, 80230, United States
-
Omeros Investigational Site
Augusta, Georgia, 30909, United States
-
Omeros Investigational Site
Lawrenceville, Georgia, 30046, United States
-
Omeros Investigational Site
Evergreen Park, Illinois, 60805, United States
-
Omeros Investigational Site
Voorhees Township, New Jersey, 08043, United States
-
Omeros Investigational Site
Flushing, New York, 11355, United States
-
Omeros Investigational Site
San Antonio, Texas, 78215, United States
-
Omeros Investigational Site
Milwaukee, Wisconsin, 53226, United States
-
Omeros Investigational Site
Chai Wan, Hong Kong
-
Omeros Investigational Site
Hong Kong, Hong Kong
-
Omeros Investigational Site
Kowloon, Hong Kong
-
Omeros Investigational Site
Shatin, Hong Kong
Conditions
Explore the condition pages connected to this study.